Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: Incremental prognostic value of novel biomarkers in heart failure

Heart

Volumn 98, Issue 5, 2012, Pages 389-394

  Miller, Wayne L ^a   Hartman, Karen A ^a   Grill, Diane E ^a   Struck, Joachim ^b   Bergmann, Andreas ^b   Jaffe, Allan S ^a  

^a MAYO CLINIC   (United States)

^b THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COPEPTIN; MIDREGION PROATRIAL NATRIURETIC PEPTIDE; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HEART FAILURE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; OUTPATIENTS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; ROC CURVE; SURVIVAL RATE; UNITED STATES;

EID: 84857111765     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300823     Document Type: Article

References (33)

1. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Failure 2005;7:710-21. (Pubitemid 41125884)
2. Bristow MR, Saxon LA, Boehmer J, et al; for the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New Engl J Med 2004;350:2140-50.
3. Konstam MA. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 2005;96:867-71. (Pubitemid 41317667)
4. Davila DF, Nunez TJ, Oderman R, et al. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol 2005;101:343-6. (Pubitemid 40719969)
5. Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: valsartan heart failure trial echocardiographic data. J Am Coll Cardiol 2004;43:2022-7. (Pubitemid 38686796)
6. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;10:2168-74. (Pubitemid 39372496)
7. O'Brien RJ, Squire IB, Demme B, et al. Pre-discharge, but not admission levels of NT-proBNP predict adverse prognosis following acute left ventricular function. Eur J Heart Failure 2003;5:499-506. (Pubitemid 37021644)
8. Anand IS, Fisher LD, Chiang YT, et al; for the Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial. Circulation 2003;107:1278-83. (Pubitemid 36314411)
9. Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure. Circulation 2007;116:249-57. (Pubitemid 47196560)
10. Masson S, Latini R, Carbonieri E, et al; on behalf of the GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data form the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010;12:338-47.
11. Neubold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 2008;52:266-72. (Pubitemid 351957847)
12. Masson S, Latini R, Anand IS, et al; for the Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008;52:997-1003.
13. Yan RT, White M, Yan AT, et al; for the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Investigators. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 2005;96:698-704. (Pubitemid 41207317)
14. O'Donoghue M, Braunwald E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 2010;7:7-13.
15. Morgenthaler NG, Struck J, Thomas B, et al. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-6. (Pubitemid 38125732)
16. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement ofcopeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-19. (Pubitemid 43032474)
17. Von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pr-B-type natriuretic peptidein predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1973-80. (Pubitemid 350046336)
18. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers fordiagnosis and prognosis in acute dyspnea. J Am Coll Cardiol 2010;55:2062-76.
19. Dieplinger B, Gegenhuber A, Haltmayer M, et al. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients withshortness of breath. Heart 2009;95:1508-13.
20. Perna ER, Macin SM, Cimbaro Canella JP, et al. Ongoing myocardial injury in stable severe heart failure. Value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004;110:2376-82. (Pubitemid 39407342)
21. Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002;89:691-5. (Pubitemid 34230565)
22. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptideconcentration: Impact of age and gender. J Am Coll Cardiol 2002;40:976-82. (Pubitemid 34994995)
23. The Joint European Society of Cardiology/American College of CardiologyCommittee. Myocardial Infarction RedefineddA Consensus Document of The JointEuropean Society of Cardiology/American College of Cardiology Committee for theRedefinition of Myocardial Infarction. J Am Coll Cardiol 2000;36:959-69.
24. Apple FS, Wu AHB, Jaffe AS. Guidelines for redefinition of myocardial infarction. How to use existing assays clinically and for clinical trials. Am Heart J 2002;144:981-6.
25. Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelinesfor chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
26. Kremer WK. Concordance for Survival Time Data: Fixed and Time-Dependentcovariates and Possible Ties in Predictor and Time. Rochester, MN: Technical report series #80, Mayo Clinic, 2007.
27. SAS Institute Inc. SAS®/STAT User's Guide, Version 9 edition. Cary, NC: SAS Institute Inc, 2005.
28. Insightful Corporation (1988-2005). S-PLUS Version 7.0 for Unix (Computer Software). Seattle, Washington: Insightful Corporation, 2005.
29. Healey JS, Davies RF, Smith SJ, et al. Prognostic use of cardiac troponin T and troponin I in patients with heart failure. Can J Cardiology 2003;19:383-6. (Pubitemid 36603504)
30. Hudson MP, O'Connor CM, Gattis WA, et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 2004;147:546-52. (Pubitemid 38880881)
31. Erna ER, Macin SM, Cimbaro Canella JP, et al. High levels of troponin T are associated with ventricular remodeling and adverse in-hospital outcome in heart failure. Med Sci Monit 2004;10:CR90-5. (Pubitemid 38339030)
32. Miller WL, Hartman KA, Grill DE, et al. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem 2009;55:78-84.
33. Januzzi JL, Rehman SU, Mohammend AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011;58:1881-9.